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Abstract
More than 100,000 genetic variants are reported to cause Mendelian disease in humans, but the 
penetrance - the probability that a carrier of the purported disease-causing genotype will indeed 
develop the disease - is generally unknown. Here we assess the impact of variants in the prion 
protein gene (PRNP) on the risk of prion disease by analyzing 16,025 prion disease cases, 60,706 
population control exomes, and 531,575 individuals genotyped by 23andMe, Inc. We show that 
missense variants in PRNP previously reported to be pathogenic are at least 30× more common in 
the population than expected based on genetic prion disease prevalence. While some of this excess 
can be attributed to benign variants falsely assigned as pathogenic, other variants have genuine 
effects on disease susceptibility but confer lifetime risks ranging from <0.1% to ~100%. We also 
show that truncating variants in PRNP have position-dependent effects, with true loss-of-function 
alleles found in healthy older individuals, supporting the safety of therapeutic suppression of prion 
protein expression.
INTRODUCTION
The study of pedigrees with Mendelian disease has been tremendously successful in 
identifying variants that contribute to severe inherited disorders (1–3). Causal variant 
discovery is enabled by selective ascertainment of affected individuals, and especially of 
multiplex families. Although efficient from a gene discovery perspective, the resulting 
ascertainment bias confounds efforts to accurately estimate the penetrance of disease-
causing variants, with profound implications for genetic counseling (4–7). The development 
of large-scale genotyping and sequencing methods has recently made it tractable to perform 
unbiased assessments of penetrance in population controls. In several instances, such studies 
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have suggested that previously reported Mendelian variants, as a class, are substantially less 
penetrant than had been believed (8–11). To date, however, all of these studies have been 
limited to relatively prevalent (>0.1%) diseases, and point estimates of the penetrance of 
individual variants have been limited to large copy number variations (8, 11).
Here we demonstrate the use of large-scale population data to infer the penetrance of 
variants in rare, dominant, monogenic disease, using the example of prion diseases. These 
invariably fatal neurodegenerative disorders are caused by misfolding of the prion protein 
(PrP, the product of PRNP) (12) and have an annual incidence of 1 to 2 cases per 1 million 
population (13). A small, albeit infamous, minority of cases (<1% in recent years (14, 15)) 
are acquired through dietary or iatrogenic routes. The majority (~85%) of cases are defined 
as sporadic, occurring in individuals with two wild-type PRNP alleles and no known 
environmental exposures. Finally, ~15% of cases occur in individuals with rare, typically 
heterozygous, coding variants in PRNP, including missense variants, truncating variants, 
and octapeptide repeat insertions or deletions (Table S1). Centralized ascertainment of cases 
by national surveillance centers (Materials and Methods) makes prion disease a good test 
case for using reference datasets to assess the penetrance of these variants.
PRNP was conclusively established as a dominant disease gene due to clear Mendelian 
segregation of a few variants with disease (16–18). Yet ascertainment bias (19), low rates of 
predictive genetic testing (20), and frequent lack of family history (21, 22) confound 
attempts to estimate penetrance by survival analysis (19, 23–26). Meanwhile, the existence 
of non-genetic etiologies leaves doubt as to whether novel variants are causal or 
coincidental.
A fully penetrant disease genotype should be no more common in the population than the 
disease that it causes. This observation allows us to leverage two large population control 
datasets to re-evaluate the penetrance of reported disease variants in PRNP. The recently 
reported Exome Aggregation Consortium (ExAC) dataset (27) contains variant calls on 
60,706 people ascertained for various common diseases, without any ascertainment on 
neurodegenerative disease. 23andMe’s database contains genotypes on 531,575 customers 
of its direct-to-consumer genotyping service who have opted in to participate in research, 
pruned to remove related individuals (first cousins or closer; Materials and Methods), 
preventing enrichment due to large families with prion disease.
RESULTS
We began by asking whether reportedly pathogenic variants are as rare as expected in these 
population control datasets. The proportion of people alive in the population today who 
harbor completely penetrant variants causal for prion disease can be approximated by the 
product of three numbers: the annual incidence of prion disease, the proportion of cases with 
such a genetic variant, and the life expectancy of individuals harboring these variants. Based 
on upper bounds of these numbers (Figure 1A), and assuming ascertainment is neutral with 
respect to neurodegenerative disease, we would expect no more than ~1.7 such individuals 
in the 60,706 exomes in the ExAC dataset (27), and ~15 such individuals among the 
~530,000 genotyped 23andMe customers who opted to participate in research.
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Through reviews (28–30) and PubMed searches, we identified 63 rare genetic variants 
reported to cause prion disease (Table S2). We reviewed ExAC read-level evidence for 
every rare (<0.1% allele frequency) variant call in PRNP (Materials and Methods; Table S3–
4) and found that 52 individuals in ExAC harbor reportedly pathogenic missense variants 
(Figure 1B), at least a 30-fold excess over expectation if all such variants were fully 
penetrant. Similarly, in the 23andMe database we observed a total of 141 alleles of 16 
reportedly pathogenic variants genotyped on their platform (Table S5).
Individuals with reportedly pathogenic PRNP variants did not cluster within any one cohort 
within ExAC (Table S6), arguing against enrichment due to comorbidity with a common 
disease ascertained for exome sequencing. ExAC does include populations, such as South 
Asians, in which prion disease is not closely surveilled and we cannot rule out a higher 
incidence than that reported in developed countries, yet the individuals with reportedly 
pathogenic variants in either ExAC or 23andMe were of diverse inferred ancestry (Table 
S7–9). These individuals’ ages were consistent with the overall ExAC age distribution 
(Figure S1), rather than being enriched below some age of disease onset. ExAC genotypes at 
the prion disease modifier polymorphism M129V (34) were consistent with population allele 
frequencies (Table S7), rather than enriched for the lower-risk heterozygous genotype. 
Certain PRNP variants are associated with highly atypical phenotypes (35, 36), which are 
mistakable for other dementias and may not be well ascertained by current surveillance 
efforts. Most of the variants found in our population control cohorts, however, have been 
reported in individuals with a classic, sporadic Creutzfeldt-Jakob disease phenotype (22, 28, 
30, 37–39), arguing that the discrepancy between observed and expected allele counts does 
not result primarily from an underappreciated prevalence of atypical prion disease.
Having observed a large excess of reportedly pathogenic variants over expectation in two 
datasets, and having excluded the most obvious confounders, we hypothesized that the 
unexpectedly high frequency of these variants in controls might arise from benign and/or 
low-risk variants.
We investigated which variants were responsible for the observed excess (Figure 2). 
Variants with the strongest prior evidence of pathogenicity are absent from ExAC and 
cumulatively account for ≤5 alleles in 23andMe, consistent with the known rarity of genetic 
prion disease. Much of the excess allele frequency in population controls is due, instead, to 
variants with very weak prior evidence of pathogenicity (Figure 2 and Supplementary 
Discussion). For four variants observed in controls (V180I, R208H, V210I, and M232R), 
pathogenicity is controversial (40, 41) or reduced penetrance has been suggested (42, 43), 
but quantitative estimates of penetrance have never been produced, and the variants remain 
categorized as causes of genetic Creutzfeldt-Jakob disease (21, 22). Although we cannot 
prove that any one of the variants we observe in population controls is completely neutral, 
the list of reported pathogenic variants likely includes false positives. Indeed, the 
observation that 0.4% (236 / 60,706) of ExAC individuals harbor a rare (<0.1%) missense 
variant (Table S4) suggests that ~4 of every 1000 sporadic prion disease cases will, by 
chance, harbor such a variant, which in many cases will be interpreted and reported as causal 
given the long-standing classification of PRNP as a Mendelian disease gene.
Minikel et al. Page 3













At least three variants, however (V180I, V210I, and M232R) fail to cluster with either the 
likely benign or likely Mendelian variants (Figure 2). Because each of these three appears 
primarily in one population in both cases and controls (Tables S1, S5, S7), we compared 
allele frequencies in matched population groups. Each has an allele frequency in controls 
that is too high for a fully penetrant, dominant prion disease-causing variant, and yet far 
lower than the corresponding allele frequency in cases (Figure 3).
Because we lack genome-wide SNP data on cases we are unable to directly correct for 
population stratification, which thus may contribute to the observed differences in allele 
frequencies. Geographic clusters of genetic prion disease have been recognized for decades 
(26, 31, 58). For example, nearly half of Italian prion disease cases with the V210I variant 
are concentrated within two regions of Italy (59), so any non-uniform geographic sampling 
in cases versus controls would add some uncertainty to our penetrance estimates.
Nonetheless, the magnitude of the enrichment of certain variants in cases over controls in 
our datasets makes substructure an implausible explanation for the entire difference. In order 
for V210I to be neutral and yet appear with an allele frequency of 8.1% in Italian cases 
despite an apparent allele frequency of 0.02% in Italian controls, it would need to be fixed in 
a subpopulation comprising 8% of Italy’s populace. Under this scenario, this subpopulation 
would need to be virtually unsampled in any of our control cohorts, and V210I cases would 
contain many homozygotes. In reality, no cases have been reported homozygous for this 
variant. Conversely, if V210I were fully penetrant, family history would be positive in most 
cases, and the variant’s appearance on 13 alleles in 23andMe (Table S5) would indicate that 
this variant alone accounts for three times the known prevalence of genetic prion disease 
(Figure 1A). Finally, if the low family history rate were due to many de novo mutations, 
then V210I cases would be more uniformly distributed across populations (Table S1). 
Similar arguments rule out V180I being either benign or Mendelian. M232R, though clearly 
not Mendelian, could still be benign as it exhibits only 4- to 6-fold enrichment in cases, an 
amount that might conceivably be explained by Japanese population substructure alone. 
However, because even common variants in PRNP affect prion disease risk with odds ratios 
of 3 or greater (60–62), it is not implausible that M232R has a similar effect size, and our 
data suggest this a more likely scenario than it being neutral.
Satisfied that these three variants are likely neither benign nor Mendelian, we estimated 
lifetime risk in heterozygotes (Materials and Methods). The ~2 in 1 million annual incidence 
of prion disease translates into a baseline lifetime risk of ~1 in 5,000 in the general 
population (Materials and Methods). Because prion diseases are so rare, even the massive 
enrichment of heterozygotes in cases (Figure 3), implying odds ratios on the order of 10 to 
1,000, corresponds to only low penetrance, with lifetime risk for M232R, V180I and V210I 
estimated near 0.1%, 1%, and 10%, respectively. Although our estimates are imperfect due 
to population stratification, they accord well with family history rates (Figure 3) and explain 
the unique space that these variants occupy in the plot of case versus control allele count 
(Figure 2). These data indicate that PRNP missense variants occupy a risk continuum rather 
than a dichotomy of causal versus benign.
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We asked whether the same was true of protein-truncating variants. PRNP possesses only 
one protein-coding exon, so premature stop codons are expected to result in truncated 
polypeptides rather than in nonsense-mediated decay. Prion diseases are known to arise from 
a gain of function, as neurodegeneration is not seen in mice, cows, or goats lacking PrP (63–
66), and the rate of prion disease progression is tightly correlated with PrP expression level 
(67). Yet heterozygous C-terminal (residue ≥145) truncating variants are known to cause 
prion disease, sometimes with peripheral amyloidosis (35). Some of these patients also 
experience sensorimotor neuropathy phenotypically similar to that present in homozygous, 
but not heterozygous, PrP knockout mice (68), but attributed to amyloid infiltration of 
peripheral nerves, rather than loss of PrP function (35).
We identified, for the first time, heterozygous N-terminal (residue ≤131) truncating variants 
in four ExAC individuals and were able to obtain Sanger validation (Figure S1) and limited 
phenotype data (Table S11) for three. These individuals are free of overt neurological 
disease at ages 79, 73, and 52, and report no personal or family history of neurodegeneration 
nor of peripheral neuropathy. Therefore, the pathogenicity of protein-truncating variants 
appears to be dictated by position within PrP’s amino acid sequence (Figure 4). Observing 
three PRNP nonsense variants in ExAC is consistent with the expected number (~3.9) once 
we adjust our model (69) to exclude codons ≥145, where truncations cause a dominant gain-
of-function disease. Thus, we see no evidence that PRNP is constrained against truncation in 
its N terminus. This, combined with the lack of any obvious phenotype in individuals with 
N-terminal truncating variants, suggests that heterozygous loss of PrP function is tolerated.
DISCUSSION
Over 100,000 genetic variants have been reported to cause Mendelian disease in humans 
(73, 74). Many such reports do not meet current standards for assertions of pathogenicity 
(75, 76), and if all such reports were believed, the cumulative frequency of these variants in 
the population would imply that most people have a genetic disease (27). It is generally 
unclear how much of the excess burden of purported disease variants in the population is 
due to benign variants falsely associated, and how much is due to variants with genuine 
association but incomplete penetrance.
Here we leverage newly available large genomic reference datasets to re-evaluate reported 
disease associations in a dominant disease gene, PRNP. We identify some missense variants 
as likely benign while showing that others span a spectrum from <0.1% to ~100% 
penetrance. Our analyses provide quantitative estimates of lifetime risk for hundreds of 
asymptomatic individuals who have inherited incompletely penetrant PRNP variants.
Available datasets are only now approaching the size and quality required for such analyses, 
resulting in limitations for our study. The confidence intervals on our lifetime risk estimates 
span more than an order of magnitude, and our inability to perfectly control for population 
stratification injects additional uncertainty. We have been unable to reclassify those PRNP 
variants that are very rare both in cases and in controls (Supplementary Discussion). We 
have avoided analysis of large insertions that are poorly called with short sequencing reads, 
though we note that existing literature on these insertions is consistent with a spectrum of 
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penetrance similar to that which we observe for missense variants (28, 77). Penetrance 
estimation in Mendelian disease will be improved by the collection of larger case series, 
particularly with genome-wide SNP data to allow more accurate population matching. This, 
coupled with continued large-scale population control sequencing and genotyping efforts, 
should reveal whether the dramatic variation in penetrance that we observe here is a more 
general feature of dominant disease genes.
Because PrP is required for prion pathogenesis and reduction in gene dosage slows disease 
progression (67, 78–80), several groups have sought to therapeutically reduce PrP 
expression using RNA interference (81–83), antisense oligonucleotides (84), or small 
molecules (85, 86). Our discovery of heterozygous loss-of-function variants in three healthy 
older humans provides the first human genetic data regarding the effects of a 50% reduction 
in gene dosage for PRNP. Both the number of individuals and the depth of available 
phenotype data are limited, and lifelong heterozygous inactivation of a gene is an imperfect 
model of the effects of pharmacological depletion of the gene product. With those 
limitations, our data provide preliminary evidence that a reduction in PRNP dosage, if 
achievable in patients, is likely to be tolerated. Increasingly large control sequencing 
datasets will soon enable testing whether the same is true of other genes currently being 
targeted in substrate reduction therapeutic approaches for other protein-folding disorders.
Together, our findings highlight the value of large reference datasets of human genetic 
variation for informing both genetic counseling and therapeutic strategy.
MATERIALS AND METHODS
Prion disease case series
Prion disease is considered a notifiable diagnosis in most developed countries, with 
mandatory reporting of all suspect cases to a centralized surveillance center. Surveillance 
was carried out broadly according to established guidelines (87, 88), with specifics as 
described previously for Australia (89), France (90), Germany (91–93), Italy (94), Japan 
(22), and the Netherlands (95). Sanger sequencing of the PRNP open reading frame was 
performed as described (96). We included only prion disease cases classified as definite 
(autopsy-confirmed) or probable according to published guidelines (88). Criteria for genetic 
testing vary between countries and over the years of data collection, with testing offered 
only on indication of family history in some times and places, and testing of all suspect 
cases with tissue available in other instances. Summary statistics on the total number and 
proportion of cases sequenced are presented in Table S1.
Exome sequencing and analysis
The ascertainment, sequencing, and joint calling of the ExAC dataset have been described 
previously (97). We extracted all rare (<0.1%) coding variant calls in PRNP with genotype 
quality (GQ) ≥10, alternate allele depth (AD) ≥3 and alternate allele balance (AB) ≥20%. 
Read-level evidence was visualized using Integrative Genomics Viewer (IGV) (98) for 
manual review. Because most ExAC exomes were sequenced with 76bp reads and the PRNP 
octapeptide repeat region (codons 50–90 inclusive) is 123bp long, it was impossible to 
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determine whether genotype calls in this region were correct, and they were not considered 
further. After review of IGV screenshots, 87% of genotype calls were judged to be correct 
and were included in Table S3. Of the genotype calls judged to be correct, 99% had 
genotype quality (GQ) ≥95, 99% had allelic balance (AB) between 30% and 70%, and 97% 
had ≥10 reads supporting the alternate allele. All participants provided informed consent for 
exome sequencing and analysis. The Exome Aggregation Consortium’s aggregation and 
release of exome data have been approved by the Partners Healthcare Institutional Research 
Board (2013P001339). ExAC data have been publicly released at http://
exac.broadinstitute.org/ and IGV screenshots of the rare PRNP variants deemed to be 
genuine and included in this study are available at https://github.com/ericminikel/
prnp_penetrance/tree/master/supplement/igv
23andMe research participants and genotyping
Participants were drawn from the customer base of 23andMe, Inc., a personal genetics 
company (accessed February 6, 2015). All participants provided informed consent under a 
protocol approved by an external AAHRPP-accredited IRB, Ethical & Independent Review 
Services (E&I Review). DNA extraction and genotyping were performed on saliva samples 
by National Genetics Institute (NGI), a CLIA-licensed clinical laboratory and a subsidiary of 
Laboratory Corporation of America. Samples were genotyped on one of four Illumina 
platforms (V1-V4) as described previously (99). Of the PRNP SNPs considered, two (P105L 
and E200K) were genotyped on all four platforms while the other 14 were genotyped only 
on V3 and V4, resulting in differing numbers of total samples genotyped (Table S5). 
Genotypes were called with Illumina GenomeStudio. A 98.5% call rate were required for all 
samples. As with all 23andMe research participants, individuals whose genotyping analyses 
failed to reach the desired call rate repeatedly were recontacted to provide additional 
samples. A maximal set of unrelated individuals was chosen based on segmental identity-by-
descent (IBD) estimation(100). Individuals were defined as related if they shared more than 
700 cM IBD (approximately the minimal expected sharing between first cousins). Allele 
counts between 1 and 5 were rounded up to 5 to protect individual privacy (Table S5). 
Rounding down to 1 instead would raise our estimates of penetrance for V180I to 7.7% 
(95%CI, 1.2% – 50%) and for P102L, A117V, D178N and E200K collectively to 100% 
(95%CI, 100% – 100%), but the confidence intervals would still overlap those based on 
ExAC allele frequencies, and the overall conclusions of our study would remain unchanged.
23andMe ancestry composition
Ancestral origins of chromosomal segments were assigned on a continental level (European, 
Latino, African, and East Asian) and a country level (Japanese) as described by Durand et al 
(101). Briefly, after phasing genotypes using an out-of-sample implementation of the Beagle 
algorithm (102), a string kernel support vector machine classifier assigns tentative ancestry 
labels to local genomic regions. Then an autoregressive pair hidden Markov model was used 
to simultaneously correct phasing errors and produce reconciled local ancestry estimates and 
confidence scores based on the initial assignment. Finally, isotonic regression models were 
used to recalibrate the confidence estimates.
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Europeans and East Asians were defined as individuals with more than 97% of 
chromosomal segments predicted as being from the respective ancestries. Because African 
Americans and Latinos are highly admixed, no single threshold of genome-wide ancestry is 
sufficient to distinguish them. However, segment length distributions of European, African, 
and Native American ancestries are different between African Americans and Latinos, due 
to distinct admixture timing in the two ethnic groups. Thus, a logistic classifier based on 
segment length of European, African, and Native American ancestries was used to 
distinguish between African Americans and Latinos.
At the country level, individuals were classified as Japanese based on the fraction of the 
respective local ancestry using a threshold of 90% for classifying Japanese ancestry. This 
threshold is based on the average fraction of local ancestry in the reference population 
(23andMe research participants with all four grandparents from the reference country): 94% 
(5% SD, N=533) for Japanese. Using the same approach, we were unable to obtain a 
confident set of Italian individuals for analysis of V210I due to extensive admixture. 
23andMe research participants with all four grandparents from Italy only have 66% (18% 
SD, N=2090) Italian ancestry, and only ~60 participants have >90% Italian ancestry.
ExAC ancestry inference
We computed ten principal components based on ~5,800 common SNPs as described (27, 
103). A centroid in eigenvalue-weighted principal component space was generated for each 
HapMap population based on 1000 Genomes individuals in ExAC. The remaining 
individuals in ExAC were assigned to the HapMap population with the nearest centroid 
according to eigenvalue-weighted Euclidean distance. Ancestries of all individuals, 
including those with reportedly pathogenic variants, are summarized in (Tables S7, S8).
Prion disease incidence and baseline risk
The reported incidence of prion disease varies between countries and between years, with 
much of the variability explained by the intensity of surveillance, as measured by the 
number of cases referred to national surveillance centers (13). Rates of ~1 case per million 
population per year have been reported, for instance in the U.S. (104) and in Japan (22), 
however, the countries with the most intense surveillance (greatest number of referrals per 
capita), such as France and Austria, observe incidence figures as high as 2 cases per million 
population per year (13). Only in small countries where the statistics are dominated by a 
particular genetic prion disease founder mutation, such as Israel and Slovakia (23, 26), has 
an incidence higher than 2 per million been consistently observed (105). We therefore 
accepted 2 cases per million as an upper bound for the true incidence of prion disease. 
Assuming an all-causes death rate of ~10 per 1,000 annually (106), this incidence 
corresponds to prion disease accounting for ~0.02% of all deaths, which we accepted as the 
baseline disease risk in the general population.
Lifetime risk estimation
By Bayes' theorem, the probability of disease given a genotype (penetrance or lifetime risk, 
P(D|G)) is equal to the proportion of individuals with the disease who have the genotype 
(genotype frequency in cases, P(G|D)) times the prevalence of the disease (baseline lifetime 
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risk in the general population, P(D)), divided by the frequency of the genotype in the general 
population (here, population control allele frequency, P(G)). The use of this formula to 
estimate disease risk dates back at least to Cornfield's estimation of the probability of lung 
cancer in smokers (107), with later contributions by Woolf (108) and a synthesis by C.C. Li 
with application to genetics (109).
We used an allelic rather than genotypic model, such that lifetime risk in an individual with 
one allele is equal to case allele frequency (based on the number of prion disease cases that 
underwent PRNP sequencing) times baseline risk divided by population control allele 
frequency, P(D|A) = P(A|D)×P(D)/P(A). Note that we assume that our population control 
datasets include individuals who will later die of prion disease, thus enabling direct use of 
the ExAC and 23andMe allele frequencies as the denominator P(A). Following Kirov (11), 
we compute Wilson 95% confidence intervals on the binomial proportions P(A|D) and P(A), 
and calculate the upper bound of the 95% confidence interval for penetrance using the upper 
bound on case allele frequency and the lower bound on population control allele frequency, 
and vice versa for the lower bound on penetrance.
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Figure 1. Reportedly pathogenic PRNP variants are >30 times more common in controls than 
expected based on disease incidence
Reported prion disease incidence varies with the intensity of surveillance efforts (13), with 
an apparent upper bound of ~2 cases per million population per year (Materials and 
Methods). In our surveillance cohorts, 65% of cases underwent PRNP open reading frame 
sequencing, with 12% of all cases, or 18% of sequenced cases, possessing a rare variant 
(Table S1), consistent with an oft-cited estimate that 15% of cases of Creutzfeldt-Jakob 
disease are familial (31). Genetic prion diseases typically strike in midlife, with mean age of 
onset for different variants ranging from 28 to 77 (22, 32) (Table S10); we accepted 80, a 
typical human life expectancy, as an upper bound for mean age of onset, and to be 
additionally conservative, we assumed that all individuals in ExAC and 23andMe were 
below any age of onset, even though both contain elderly individuals (33) (Figure S1). Thus, 
no more than ~29 people per million in the general population should harbor high-
penetrance prion disease-causing variants. Therefore at most ~1.7 people in ExAC (A) and 
~15 people in 23andMe would be expected to harbor such variants. In fact, reportedly 
pathogenic variants are seen in 52 ExAC individuals (B) and on 141 alleles in the 23andMe 
database.
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Figure 2. Reportedly pathogenic PRNP variants include Mendelian, benign, and intermediate 
variants
Prior evidence of pathogenicity is extremely strong for four missense variants - P102L, 
A117V, D178N and E200K - each of which has been observed to segregate with disease in 
multiple multigenerational families (16–18, 44–48) and to cause spontaneous disease in 
mouse models (49–54). These account for >50% of genetic prion disease cases (Table S1), 
yet are absent from ExAC (Table S3), and collectively appear on ≤5 alleles in 23andMe’s 
cohort (Table S5), indicating allele frequencies sufficiently low to be consistent with the 
prevalence of genetic prion disease (Figure 1). Conversely, the variants most common in 
controls and rare in cases had categorically weak prior evidence for pathogenicity. R208C (8 
alleles in 23andMe) and P39L were observed in patients presenting clinically with other 
dementias, with prion disease suggested as an alternative diagnosis solely on the basis of 
finding a novel PRNP variant (55, 56). E196A was originally reported in a single patient, 
with a sporadic Creutzfeldt-Jakob disease phenotype and no family history (37), and 
appeared in only 2 of 790 Chinese prion disease patients in a recent case series (57), 
consistent with the ~0.1% allele frequency among Chinese individuals in ExAC (Tables S5 
and S8). At least three variants (M232R, V180I, and V210I) occupy a space inconsistent 
with either neutrality or with complete penetrance (see main text and Figure 3). R148H, 
T188R, V203I, R208H and additional variants are discussed in Supplementary Discussion.
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Figure 3. Certain variants confer intermediate amounts of lifetime risk
M232R, V180I, and V210I show varying degrees of enrichment in cases over controls, 
indicating a weak to moderate increase in risk. Best estimates of lifetime risk in 
heterozygotes (Materials and Methods) range from ~0.08% for M232R to ~7.8% for V210I, 
and correlate with the proportion of patients with a positive family history. Allele 
frequencies for P102L, A117V, D178N and E200K are consistent with up to 100% 
penetrance, with confidence intervals including all reported estimates of E200K penetrance 
based on survival analysis, which range from ~60% to ~90% (19, 23–26). Rates of family 
history of neurodegenerative disease in Japanese cases are from (Table S10) and in 
European populations are from Kovacs et al (21), with Wilson binomial 95% confidence 
intervals shown. *Based on allele counts rounded for privacy (Materials and Methods). 
†GSS, Gerstmann Straussler Scheinker disease associated with variants P102L, A117V and 
G131V. ‡FFI: fatal familial insomnia associated with a D178N cis 129M haplotype.
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Figure 4. Effects of truncating variants in the human prion protein are position-dependent
Truncating variants reported in prion disease cases in the literature (Table S2) and in our 
cohorts (Table S1) cluster exclusively in the C-terminal region (residue ≥145), while 
truncating variants in ExAC are more N-terminal (residue ≤131). The ortholog of each 
residue from 23–94 is deleted in at least one prion-susceptible transgenic mouse line (70). C-
terminal truncations abolish PrP’s glycosylphosphatidylinositol anchor but leave most of the 
protein intact, a combination that mediates gain of function through mislocalization, causing 
this normally cell-surface-anchored protein to be secreted. Consistent with this model of 
pathogenicity, mice expressing full-length secreted PrP develop fatal and transmissible prion 
disease (71, 72). By contrast, the N-terminal truncating variants that we observe retain only 
residues dispensable for prion propagation, and are likely to cause a total loss of protein 
function.
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